---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-057020"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:18:07.257148+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q2 revenue up 11% to $15M; net income $237K, adj EBITDA $843K; positive outlook

## Summary
- Q2 total revenue $15.0M (+11% YoY); oncology services profit $7.8M, margin 52% vs 45%.
- Net income $237K; adjusted EBITDA $843K; prior-year net income $728K, adj. EBITDA $1.1M.
- Year-to-date revenue $29.0M (+5%); net loss $230K; adj. EBITDA $962K vs $3.2M prior.
- Cash $8.5M, no debt; management on track for full-year revenue growth and positive adj. EBITDA.
- R&D spend up 55% YoY, G&A up 57% on investments in data platform and business development.

## SEC filing metadata
- accession: 0001628280-25-057020
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828025057020/0001628280-25-057020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828025057020/csbr-20251215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-057020
- JSON: https://secwatch.observer/filing/0001628280-25-057020.json
- Plain text: https://secwatch.observer/filing/0001628280-25-057020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.